PhD in Antibody-Drug Conjugate Engineering for Cancer

The Biotech Research and Innovation Centre (BRIC) at the University of Copenhagen invites applications for a 3-year PhD fellowship in antibody-drug conjugate (ADC) research. The successful candidate will join the group of Associate Professor Lars Henning Engelholm, with a start around 15 January 2027.

The project aims to engineer next-generation ADCs with improved internalization and lysosomal routing, including bispecific constructs, with in vivo testing and collaboration with Novo Nordisk